<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01510717</url>
  </required_header>
  <id_info>
    <org_study_id>C-10-016</org_study_id>
    <nct_id>NCT01510717</nct_id>
  </id_info>
  <brief_title>Clinical Investigation of AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (IOL) Model SN6AD2 [SV25T0]</brief_title>
  <official_title>Clinical Investigation of AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (IOL) Model SN6AD2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of an investigational
      multifocal intraocular lens (IOL) to an FDA-approved monofocal IOL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants 21 years and older in need of cataract extraction were consented and randomized
      in a 1:1 ratio at each investigative site to receive either the AcrySof® IQ ReSTOR® +2.5 D
      Multifocal IOL Model SN6AD2 [SV25T0] or the AcrySof® IQ Monofocal IOL Model SN60WF in both
      eyes. Each participant completed a preoperative examination of both eyes, implantation of IOL
      at the operative visit for each eye, and up to 7 postoperative visits, with monocular testing
      at Day 1-2, Day 7-14, and Day 30-60, and monocular and binocular testing at Day 120-180
      following the second implantation. The first eye to be implanted was considered the primary
      eye. The second eye was implanted 7 and 30 days of the first. If the first eye was not
      implanted during surgery, the second eye was not eligible. If the second eye was not
      implanted during surgery, only the first eye was followed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Photopic Monocular Distance Corrected VA (53 cm) at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>Visual acuity (VA) was tested monocularly (each eye separately) using the manifest refraction adjusted for optical infinity and the hand-held, 100% contrast, Early Treatment Diabetic Retinopathy Study (ETDRS) chart set at 53 centimeters (cm) on the nearpoint rod. VA was measured in logMAR (logarithm of the minimum angle of resolution), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the primary eye.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Cumulative and Persistent Adverse Events as Defined in IS EN ISO 11979-7:2006, up to Day 120-180</measure>
    <time_frame>Day 0 first operative eye visit, up to Day 120-180 from second eye implantation</time_frame>
    <description>Cumulative and persistent adverse events were collected. This outcome measure was prespecified for the multifocal IOL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Photopic Contrast Sensitivity Without Glare at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>Contrast sensitivity (ie, the ability to detect objects by distinguishing them from their background) was assessed binocularly with the participant's best spectacle correction under photopic (bright) conditions at a distance of 8 feet at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd) using the Vector Vision CSV 1000 without a glare source. Raw scores from contrast sensitivity testing were transformed to log units. Scores of (-1) were set to missing; hence, the mean measures may be overestimated and the variability measures may be underestimated. A higher numeric value represents better contrast sensitivity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Photopic Contrast Sensitivity With Glare at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>Contrast sensitivity was assessed binocularly with the participant's best spectacle correction under photopic (bright) conditions at a distance of 8 feet at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd) using the Vector Vision CSV 1000 with a glare source. Raw scores from contrast sensitivity testing were transformed to log units. Scores of (-1) were set to missing; hence, the mean measures may be overestimated and the variability measures may be underestimated. A higher numeric value represents better contrast sensitivity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mesopic Contrast Sensitivity Without Glare at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>Contrast sensitivity was assessed binocularly with the participant's best spectacle correction under mesopic (dim lighting) conditions at a distance of 8 feet at spatial frequencies of 1.5, 3, 6, and 12 cycles per degree (cpd) using the Vector Vision CSV 1000 without a glare source. Raw scores from contrast sensitivity testing were transformed to log units. Scores of (-1) were set to missing; hence, the mean measures may be overestimated and the variability measures may be underestimated. A higher numeric value represents better contrast sensitivity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mesopic Contrast Sensitivity With Glare at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>Contrast sensitivity was assessed binocularly with the participant's best spectacle correction under mesopic conditions at a distance of 8 feet at spatial frequencies of 1.5, 3, 6, and 12 cpd using the Vector Vision CSV 1000 with a glare source. Raw scores from contrast sensitivity testing were transformed to log units. Scores of (-1) were set to missing; hence, the mean measures may be overestimated and the variability measures may be underestimated. A higher numeric value represents better contrast sensitivity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Photopic Monocular Best Corrected Distance VA (4 m) at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>VA was tested monocularly (each eye separately) using the correction obtained from the manifest refraction and 100% contrast, ETDRS charts at a distance of 4 meters. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the primary eye.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Photopic Monocular Distance Corrected Near VA at Standard Distance (40 cm) at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>VA was tested monocularly (each eye separately) using the manifest refraction adjusted for optical infinity and the hand-held, 100% contrast, ETDRS chart set at 40 cm on the nearpoint rod. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the primary eye.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Spectacle Independence Using SILVER Patient Reported Outcome (PRO) Questionnaire at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>Overall Spectacle Independence was rated using SILVER (Spectacle Independence Lens Vision Evaluation and Repurchase), a new patient reported outcome questionnaire. The participant was asked, &quot;How often do you wear eyeglasses or contact lenses overall?&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Near Spectacle Independence Using SILVER Patient Reported Outcome (PRO) Questionnaire at Day 120-180</measure>
    <time_frame>Day 120-180 from second eye implantation</time_frame>
    <description>Near Spectacle Independence was rated using SILVER, a new patient reported outcome questionnaire. The participant was asked, &quot;How often do you wear eyeglasses or contact lenses for seeing objects up close?&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">409</enrollment>
  <condition>Cataracts</condition>
  <arm_group>
    <arm_group_label>Multifocal IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monofocal IOL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AcrySof® IQ Monofocal IOL Model SN60WF, bilateral implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]</intervention_name>
    <description>Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient</description>
    <arm_group_label>Multifocal IOL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcrySof® IQ Monofocal IOL Model SN60WF</intervention_name>
    <description>Monofocal IOL implanted for long-term use over the lifetime of the cataract patient</description>
    <arm_group_label>Monofocal IOL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of bilateral cataracts

          -  Willing and able to complete all required postoperative visits

          -  Calculated lens power within the available supply range

          -  Planned cataract removal by phacoemulsification

          -  Potential postoperative visual acuity of 0.2 logMAR or better in both eyes

          -  Preoperative astigmatism less than 1.0 diopter

          -  Clear intraocular media other than cataract in study eyes

          -  Preoperative Best Corrected Distance Visual Acuity (BCDVA) worse than 0.2 logMAR

          -  Able to undergo second eye surgery between 7 days and 30 days of the first eye surgery

          -  Other protocol-defined inclusion criteria may apply

        Exclusion Criteria:

          -  Previous refractive surgery

          -  Inflammation or edema of the cornea

          -  Optic nerve atrophy

          -  Pregnancy

          -  Current participation in another investigational drug or device study

          -  Other protocol-defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magda Michna, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2012</study_first_submitted>
  <study_first_submitted_qc>January 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2012</study_first_posted>
  <results_first_submitted>May 8, 2015</results_first_submitted>
  <results_first_submitted_qc>May 8, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2015</results_first_posted>
  <last_update_submitted>May 8, 2015</last_update_submitted>
  <last_update_submitted_qc>May 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intraocular Lens</keyword>
  <keyword>Monofocal</keyword>
  <keyword>Multifocal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited and enrolled from 15 investigative sites located in the United States.</recruitment_details>
      <pre_assignment_details>Of the 409 participants enrolled, 80 were discontinued prior to randomization as screen failures and 9 were discontinued after randomization prior to implantation. This reporting group includes all participants with successful IOL implantation in at least 1 eye (320).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Multifocal IOL</title>
          <description>AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]</description>
        </group>
        <group group_id="P2">
          <title>Monofocal IOL</title>
          <description>AcrySof® IQ Monofocal IOL Model SN60WF</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all participants with successful IOL implantation in at least 1 eye.</population>
      <group_list>
        <group group_id="B1">
          <title>Multifocal IOL</title>
          <description>AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]</description>
        </group>
        <group group_id="B2">
          <title>Monofocal IOL</title>
          <description>AcrySof® IQ Monofocal IOL Model SN60WF</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="155"/>
            <count group_id="B2" value="165"/>
            <count group_id="B3" value="320"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.7" spread="9.64"/>
                    <measurement group_id="B2" value="69.4" spread="8.27"/>
                    <measurement group_id="B3" value="69.0" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>20-29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥80 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Photopic Monocular Distance Corrected VA (53 cm) at Day 120-180</title>
        <description>Visual acuity (VA) was tested monocularly (each eye separately) using the manifest refraction adjusted for optical infinity and the hand-held, 100% contrast, Early Treatment Diabetic Retinopathy Study (ETDRS) chart set at 53 centimeters (cm) on the nearpoint rod. VA was measured in logMAR (logarithm of the minimum angle of resolution), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the primary eye.</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>This analysis population includes all participants with successful IOL implantation in the primary eye.</population>
        <group_list>
          <group group_id="O1">
            <title>Multifocal IOL</title>
            <description>AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]</description>
          </group>
          <group group_id="O2">
            <title>Monofocal IOL</title>
            <description>AcrySof® IQ Monofocal IOL Model SN60WF</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Photopic Monocular Distance Corrected VA (53 cm) at Day 120-180</title>
          <description>Visual acuity (VA) was tested monocularly (each eye separately) using the manifest refraction adjusted for optical infinity and the hand-held, 100% contrast, Early Treatment Diabetic Retinopathy Study (ETDRS) chart set at 53 centimeters (cm) on the nearpoint rod. VA was measured in logMAR (logarithm of the minimum angle of resolution), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the primary eye.</description>
          <population>This analysis population includes all participants with successful IOL implantation in the primary eye.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.322" spread="0.014"/>
                    <measurement group_id="O2" value="0.512" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Cumulative and Persistent Adverse Events as Defined in IS EN ISO 11979-7:2006, up to Day 120-180</title>
        <description>Cumulative and persistent adverse events were collected. This outcome measure was prespecified for the multifocal IOL.</description>
        <time_frame>Day 0 first operative eye visit, up to Day 120-180 from second eye implantation</time_frame>
        <population>This analysis population includes all participants with attempted IOL implantation in at least one eye (successful or aborted after contact with the eye).</population>
        <group_list>
          <group group_id="O1">
            <title>Multifocal IOL</title>
            <description>AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cumulative and Persistent Adverse Events as Defined in IS EN ISO 11979-7:2006, up to Day 120-180</title>
          <description>Cumulative and persistent adverse events were collected. This outcome measure was prespecified for the multifocal IOL.</description>
          <population>This analysis population includes all participants with attempted IOL implantation in at least one eye (successful or aborted after contact with the eye).</population>
          <units>adverse events</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cystoid macular oedema (cumulative)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endophthalmitis (cumulative)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypopyon (cumulative)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lens dislocated from posterior (cumulative)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pupillary block (cumulative)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retinal detachment (cumulative)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary surgical intervention (cumulative)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corneal stroma oedema (persistent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cystoid macular oedema (persistent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Iritis (persistent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Raised IOP requiring treatment (persistent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Photopic Contrast Sensitivity Without Glare at Day 120-180</title>
        <description>Contrast sensitivity (ie, the ability to detect objects by distinguishing them from their background) was assessed binocularly with the participant's best spectacle correction under photopic (bright) conditions at a distance of 8 feet at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd) using the Vector Vision CSV 1000 without a glare source. Raw scores from contrast sensitivity testing were transformed to log units. Scores of (-1) were set to missing; hence, the mean measures may be overestimated and the variability measures may be underestimated. A higher numeric value represents better contrast sensitivity.</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>The analysis population includes all participants with successful IOL implantation that had at least 1 postoperative visit, had no preoperative pathology or macular degeneration, and had no major protocol deviations at any time. Here n=number of participants with data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Multifocal IOL</title>
            <description>AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]</description>
          </group>
          <group group_id="O2">
            <title>Monofocal IOL</title>
            <description>AcrySof® IQ Monofocal IOL Model SN60WF</description>
          </group>
        </group_list>
        <measure>
          <title>Photopic Contrast Sensitivity Without Glare at Day 120-180</title>
          <description>Contrast sensitivity (ie, the ability to detect objects by distinguishing them from their background) was assessed binocularly with the participant's best spectacle correction under photopic (bright) conditions at a distance of 8 feet at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd) using the Vector Vision CSV 1000 without a glare source. Raw scores from contrast sensitivity testing were transformed to log units. Scores of (-1) were set to missing; hence, the mean measures may be overestimated and the variability measures may be underestimated. A higher numeric value represents better contrast sensitivity.</description>
          <population>The analysis population includes all participants with successful IOL implantation that had at least 1 postoperative visit, had no preoperative pathology or macular degeneration, and had no major protocol deviations at any time. Here n=number of participants with data for analysis.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 cpd (n=131,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.676" spread="0.259"/>
                    <measurement group_id="O2" value="1.743" spread="0.203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 cpd (n=130,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.816" spread="0.256"/>
                    <measurement group_id="O2" value="1.938" spread="0.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 cpd (n=129,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.460" spread="0.312"/>
                    <measurement group_id="O2" value="1.555" spread="0.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 cpd (n=130,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.970" spread="0.348"/>
                    <measurement group_id="O2" value="1.109" spread="0.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Photopic Monocular Best Corrected Distance VA (4 m) at Day 120-180</title>
        <description>VA was tested monocularly (each eye separately) using the correction obtained from the manifest refraction and 100% contrast, ETDRS charts at a distance of 4 meters. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the primary eye.</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>This analysis population includes all participants with successful IOL implantation in the primary eye.</population>
        <group_list>
          <group group_id="O1">
            <title>Multifocal IOL</title>
            <description>AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]</description>
          </group>
          <group group_id="O2">
            <title>Monofocal IOL</title>
            <description>AcrySof® IQ Monofocal IOL Model SN60WF</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Photopic Monocular Best Corrected Distance VA (4 m) at Day 120-180</title>
          <description>VA was tested monocularly (each eye separately) using the correction obtained from the manifest refraction and 100% contrast, ETDRS charts at a distance of 4 meters. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the primary eye.</description>
          <population>This analysis population includes all participants with successful IOL implantation in the primary eye.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" spread="0.009"/>
                    <measurement group_id="O2" value="0.003" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Photopic Monocular Distance Corrected Near VA at Standard Distance (40 cm) at Day 120-180</title>
        <description>VA was tested monocularly (each eye separately) using the manifest refraction adjusted for optical infinity and the hand-held, 100% contrast, ETDRS chart set at 40 cm on the nearpoint rod. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the primary eye.</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>This analysis population includes all participants with successful IOL implantation in the primary eye.</population>
        <group_list>
          <group group_id="O1">
            <title>Multifocal IOL</title>
            <description>AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]</description>
          </group>
          <group group_id="O2">
            <title>Monofocal IOL</title>
            <description>AcrySof® IQ Monofocal IOL Model SN60WF</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Photopic Monocular Distance Corrected Near VA at Standard Distance (40 cm) at Day 120-180</title>
          <description>VA was tested monocularly (each eye separately) using the manifest refraction adjusted for optical infinity and the hand-held, 100% contrast, ETDRS chart set at 40 cm on the nearpoint rod. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the primary eye.</description>
          <population>This analysis population includes all participants with successful IOL implantation in the primary eye.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.426" spread="0.014"/>
                    <measurement group_id="O2" value="0.632" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Spectacle Independence Using SILVER Patient Reported Outcome (PRO) Questionnaire at Day 120-180</title>
        <description>Overall Spectacle Independence was rated using SILVER (Spectacle Independence Lens Vision Evaluation and Repurchase), a new patient reported outcome questionnaire. The participant was asked, &quot;How often do you wear eyeglasses or contact lenses overall?&quot;</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>This analysis population includes all participants with successful IOL implantation in at least 1 eye with data present.</population>
        <group_list>
          <group group_id="O1">
            <title>Multifocal IOL</title>
            <description>AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]</description>
          </group>
          <group group_id="O2">
            <title>Monofocal IOL</title>
            <description>AcrySof® IQ Monofocal IOL Model SN60WF</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Spectacle Independence Using SILVER Patient Reported Outcome (PRO) Questionnaire at Day 120-180</title>
          <description>Overall Spectacle Independence was rated using SILVER (Spectacle Independence Lens Vision Evaluation and Repurchase), a new patient reported outcome questionnaire. The participant was asked, &quot;How often do you wear eyeglasses or contact lenses overall?&quot;</description>
          <population>This analysis population includes all participants with successful IOL implantation in at least 1 eye with data present.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None of the time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some of the time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Most of the time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All of the time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Near Spectacle Independence Using SILVER Patient Reported Outcome (PRO) Questionnaire at Day 120-180</title>
        <description>Near Spectacle Independence was rated using SILVER, a new patient reported outcome questionnaire. The participant was asked, &quot;How often do you wear eyeglasses or contact lenses for seeing objects up close?&quot;</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>This analysis population includes all participants with successful IOL implantation in at least 1 eye with data present.</population>
        <group_list>
          <group group_id="O1">
            <title>Multifocal IOL</title>
            <description>AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]</description>
          </group>
          <group group_id="O2">
            <title>Monofocal IOL</title>
            <description>AcrySof® IQ Monofocal IOL Model SN60WF</description>
          </group>
        </group_list>
        <measure>
          <title>Near Spectacle Independence Using SILVER Patient Reported Outcome (PRO) Questionnaire at Day 120-180</title>
          <description>Near Spectacle Independence was rated using SILVER, a new patient reported outcome questionnaire. The participant was asked, &quot;How often do you wear eyeglasses or contact lenses for seeing objects up close?&quot;</description>
          <population>This analysis population includes all participants with successful IOL implantation in at least 1 eye with data present.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None of the time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some of the time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Most of the time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All of the time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Photopic Contrast Sensitivity With Glare at Day 120-180</title>
        <description>Contrast sensitivity was assessed binocularly with the participant's best spectacle correction under photopic (bright) conditions at a distance of 8 feet at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd) using the Vector Vision CSV 1000 with a glare source. Raw scores from contrast sensitivity testing were transformed to log units. Scores of (-1) were set to missing; hence, the mean measures may be overestimated and the variability measures may be underestimated. A higher numeric value represents better contrast sensitivity.</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>The analysis population includes all participants with successful IOL implantation that had at least 1 postoperative visit, had no preoperative pathology or macular degeneration, and had no major protocol deviations at any time. Here n=number of participants with data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Multifocal IOL</title>
            <description>AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]</description>
          </group>
          <group group_id="O2">
            <title>Monofocal IOL</title>
            <description>AcrySof® IQ Monofocal IOL Model SN60WF</description>
          </group>
        </group_list>
        <measure>
          <title>Photopic Contrast Sensitivity With Glare at Day 120-180</title>
          <description>Contrast sensitivity was assessed binocularly with the participant's best spectacle correction under photopic (bright) conditions at a distance of 8 feet at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd) using the Vector Vision CSV 1000 with a glare source. Raw scores from contrast sensitivity testing were transformed to log units. Scores of (-1) were set to missing; hence, the mean measures may be overestimated and the variability measures may be underestimated. A higher numeric value represents better contrast sensitivity.</description>
          <population>The analysis population includes all participants with successful IOL implantation that had at least 1 postoperative visit, had no preoperative pathology or macular degeneration, and had no major protocol deviations at any time. Here n=number of participants with data for analysis.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 cpd (n=130,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.608" spread="0.307"/>
                    <measurement group_id="O2" value="1.692" spread="0.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 cpd (n=117,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.684" spread="0.316"/>
                    <measurement group_id="O2" value="1.844" spread="0.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 cpd (n=117,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.334" spread="0.321"/>
                    <measurement group_id="O2" value="1.475" spread="0.336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 cpd (n=119,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.914" spread="0.333"/>
                    <measurement group_id="O2" value="1.043" spread="0.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mesopic Contrast Sensitivity Without Glare at Day 120-180</title>
        <description>Contrast sensitivity was assessed binocularly with the participant's best spectacle correction under mesopic (dim lighting) conditions at a distance of 8 feet at spatial frequencies of 1.5, 3, 6, and 12 cycles per degree (cpd) using the Vector Vision CSV 1000 without a glare source. Raw scores from contrast sensitivity testing were transformed to log units. Scores of (-1) were set to missing; hence, the mean measures may be overestimated and the variability measures may be underestimated. A higher numeric value represents better contrast sensitivity.</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>The analysis population includes all participants with successful IOL implantation that had at least 1 postoperative visit, had no preoperative pathology or macular degeneration, and had no major protocol deviations at any time. Here n=number of participants with data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Multifocal IOL</title>
            <description>AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]</description>
          </group>
          <group group_id="O2">
            <title>Monofocal IOL</title>
            <description>AcrySof® IQ Monofocal IOL Model SN60WF</description>
          </group>
        </group_list>
        <measure>
          <title>Mesopic Contrast Sensitivity Without Glare at Day 120-180</title>
          <description>Contrast sensitivity was assessed binocularly with the participant's best spectacle correction under mesopic (dim lighting) conditions at a distance of 8 feet at spatial frequencies of 1.5, 3, 6, and 12 cycles per degree (cpd) using the Vector Vision CSV 1000 without a glare source. Raw scores from contrast sensitivity testing were transformed to log units. Scores of (-1) were set to missing; hence, the mean measures may be overestimated and the variability measures may be underestimated. A higher numeric value represents better contrast sensitivity.</description>
          <population>The analysis population includes all participants with successful IOL implantation that had at least 1 postoperative visit, had no preoperative pathology or macular degeneration, and had no major protocol deviations at any time. Here n=number of participants with data for analysis.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1.5 cpd (n=128,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.594" spread="0.224"/>
                    <measurement group_id="O2" value="1.622" spread="0.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 cpd (n=131,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.563" spread="0.267"/>
                    <measurement group_id="O2" value="1.618" spread="0.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 cpd (n=122,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.581" spread="0.296"/>
                    <measurement group_id="O2" value="1.673" spread="0.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 cpd (n=102,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.077" spread="0.363"/>
                    <measurement group_id="O2" value="1.208" spread="0.345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mesopic Contrast Sensitivity With Glare at Day 120-180</title>
        <description>Contrast sensitivity was assessed binocularly with the participant's best spectacle correction under mesopic conditions at a distance of 8 feet at spatial frequencies of 1.5, 3, 6, and 12 cpd using the Vector Vision CSV 1000 with a glare source. Raw scores from contrast sensitivity testing were transformed to log units. Scores of (-1) were set to missing; hence, the mean measures may be overestimated and the variability measures may be underestimated. A higher numeric value represents better contrast sensitivity.</description>
        <time_frame>Day 120-180 from second eye implantation</time_frame>
        <population>The analysis population includes all participants with successful IOL implantation that had at least 1 postoperative visit, had no preoperative pathology or macular degeneration, and had no major protocol deviations at any time. Here n=number of participants with data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Multifocal IOL</title>
            <description>AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]</description>
          </group>
          <group group_id="O2">
            <title>Monofocal IOL</title>
            <description>AcrySof® IQ Monofocal IOL Model SN60WF</description>
          </group>
        </group_list>
        <measure>
          <title>Mesopic Contrast Sensitivity With Glare at Day 120-180</title>
          <description>Contrast sensitivity was assessed binocularly with the participant's best spectacle correction under mesopic conditions at a distance of 8 feet at spatial frequencies of 1.5, 3, 6, and 12 cpd using the Vector Vision CSV 1000 with a glare source. Raw scores from contrast sensitivity testing were transformed to log units. Scores of (-1) were set to missing; hence, the mean measures may be overestimated and the variability measures may be underestimated. A higher numeric value represents better contrast sensitivity.</description>
          <population>The analysis population includes all participants with successful IOL implantation that had at least 1 postoperative visit, had no preoperative pathology or macular degeneration, and had no major protocol deviations at any time. Here n=number of participants with data for analysis.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1.5 cpd (n=127,129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.536" spread="0.237"/>
                    <measurement group_id="O2" value="1.596" spread="0.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 cpd (n=128,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.542" spread="0.292"/>
                    <measurement group_id="O2" value="1.600" spread="0.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 cpd (n=114,126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.543" spread="0.329"/>
                    <measurement group_id="O2" value="1.617" spread="0.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 cpd (n=90,105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.043" spread="0.385"/>
                    <measurement group_id="O2" value="1.153" spread="0.375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected for the duration of the study (Feb 2012-Dec 2012).</time_frame>
      <desc>An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical sign, whether or not related to the investigational device. AEs were collected as solicited comments and as observations by the Investigator as outlined in the protocol. &quot;At Risk&quot; population for ocular AEs is included with unit of &quot;eyes.&quot;</desc>
      <group_list>
        <group group_id="E1">
          <title>Pre-Treatment</title>
          <description>All enrolled participants</description>
        </group>
        <group group_id="E2">
          <title>Multifocal IOL</title>
          <description>All participants with attempted IOL implantation in at least one eye (successful or aborted after contact with the eye), AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]</description>
        </group>
        <group group_id="E3">
          <title>Monofocal IOL</title>
          <description>All participants with attempted IOL implantation in at least one eye (successful or aborted after contact with the eye), AcrySof® IQ Monofocal IOL Model SN60WF</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cystoid macular oedema (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Cystoid macular oedema (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Iritis (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device dislocation (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Incisional hernia gangrenous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cataract operation complication (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Surgical procedure repeated (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Wound complication (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Eye operation (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Intraocular injection (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Magda Michna, PhD</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

